Industry News
Victorian Premier presents Award for Medical Research
Two Melbourne researchers, Dr Merlin Thomas and Dr Stephen Ting, have jointly won the 2005 Victorian Premier's Award for Medical Research. [ + ]
GroPep releases infertility data
Key pre-clinical data on GroPep's (ASX:GRO) infertility drug, PV903, showing a halving of the miscarriage rate in a strain of female mice susceptible to the immune rejection of the foetus, will be presented at a reproductive immunology meeting this week in the US. [ + ]
Metabolic shares suspended
Melbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement. [ + ]
US group to fund Australian spinal cord map
Researchers at the Spinal Injuries Research Centre at the Prince of Wales Medical Research Institute have received AUD$200,000 from the Christopher Reeve Paralysis Foundation to produce a three-dimensional map of the rat spinal cord that will be made publicly available on the internet. [ + ]
Two PhD students win inaugural Qiagen prize
Two PhD students at the University of Melbourne's Department of Microbiology and Immunology were today awarded cash prizes towards travel to an international conference by life science company Qiagen. [ + ]
In brief: C3, GTG, Avantogen, Alchemia
Clinical Cell Culture (C3, ASX:CCE) will launch CellSpray XP commercially in Europe next week at a meeting in Germany. Following the launch CellSpray XP will be available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK. [ + ]
ASMR president rallies for medical research funding
The president of the Australian Society for Medical Research has made a call for action from researchers to campaign for more federal government funding for medical research. [ + ]
Let's end restrictions on science: ASMR medallist
The message from this year's Australian Society for Medical Research medallist, Julian Savulescu, was controversial but clear: we should use science to enhance humans. [ + ]
Opara steps down as Polartechnics chair
Richard Opara has stepped down from his role as interim chairman of device company Polartechnics (ASX:PLT), and is replaced by corporate financial advisor Robert Hunter. [ + ]
Biota boosted by antiviral find
Biota Holdings (ASX:BTA) has developed a new class of orally-effective antivirals against respiratory syncytial virus (RSV) infection that the company hopes will go to Phase I trials by 2006. [ + ]
Researchers get first peek at amyloid's spine
Researchers at the Howard Hughes Medical Institute in US have provided the first detailed look at the core structure of the abnormal protein filaments found in at least 20 devastating diseases, ranging from Alzheimer's to Creutzfeldt-Jakob disease, the human version of “mad cow†disease.
[ + ]Victoria endorses NATA accreditation
The Victorian Government has signed a Memorandum of Understanding (MOU) with the National Association of Testing Authorities, Australia (NATA) affirming its support for laboratory accreditation as a key element of good business practice.
[ + ]Peptech to advance anti-TNF drug after preclinical study
Peptech (ASX:PTD) has claimed "significant" results in a preclinical study of its human domain antibody (dAb) therapeutic -- potency levels three times higher than the current market-leading anti-TNF drug against rheumatoid arthritis. [ + ]
Bio21 Institute opens today
Australia's newest research institute, the AUD$100 million Bio21 Institute, based at the University of Melbourne, officially opened its doors today. [ + ]
Avantogen to co-develop genital herpes vaccine
Avantogen (ASX:ACU), formerly known as Australian Cancer Tehcnology, is to team up with the University of Alabama at Birmingham (UAB) to conduct a preclinical study to develop a new therapeutic vaccine for herpes simplex virus type 2 (HSV-2). [ + ]
